Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
Stephen Chan(Heidelberg University), John Crown(St. Vincent's University Hospital), D. Noel(Goethe University Frankfurt), Monica Ronzoni, A. Riva(Goethe University Frankfurt), Daniel Vorobiof(The Medical Oncology Centre of Rosebank), Louise Yelle(Institut Claudius Regaud), Franco Buzzi(Goethe University Frankfurt), I. Bodrogi(Aarhus University Hospital), S Korec(Goethe University Frankfurt), Kay Friedrichs(Goethe University Frankfurt), Elizabeth Murray(University College London), M Murawsky(Goethe University Frankfurt), Simon Van Belle(Goethe University Frankfurt), Peter Simmonds(University of Turku), Rosario González Mancha(Goethe University Frankfurt), Tamás Pintér(Goethe University Frankfurt), Euan Walpole(The University of Queensland), Ricardo Jordão Duarte(Goethe University Frankfurt), Gϋnter von Minckwitz(German Breast group), May Alakl(Goethe University Frankfurt), Miguel Gil Gil(Apple (Israel)), Gary Richardson(Cabrini Hospital)
Cited by 639
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k